PMID- 17803572
OWN - NLM
STAT- MEDLINE
DCOM- 20071113
LR  - 20191210
IS  - 0886-0440 (Print)
IS  - 0886-0440 (Linking)
VI  - 22
IP  - 5
DP  - 2007 Sep-Oct
TI  - Early hemodynamic results of the Shelhigh SuperStentless aortic bioprostheses.
PG  - 379-84
AB  - BACKGROUND: Stentless valves have been demonstrated excellent hemodynamic 
      performances favoring the recovery of left ventricular function and the 
      ventricular hypertrophy regression. The aim of the study was to evaluate the 
      early hemodynamic performance of the Shelhigh SuperStentless aortic valve (AV). 
      METHODS: Between July 2003 and June 2005, 35 patients (18 females; age 70.8 +/- 
      11.7 years, range: 22-85) underwent AV replacement with the Shelhigh 
      SuperStentless bioprostheses. Most recurrent etiology was senile degeneration in 
      25 (71%) patients and 24 (69%) were in New York Heart Association (NYHA) 
      functional class III or IV. Concomitant coronary artery bypass grafting was 
      performed in nine patients (25.7%) and mitral valve surgery in two patients 
      (5.7%). Doppler echocardiography was performed before surgery, at six-month and 
      one-year follow-up. RESULTS: There were no hospital deaths and no valve-related 
      perioperative complications. During one-year follow-up, no endocarditis or 
      thromboembolic events were registered, no cases of structural dysfunction or 
      valve thrombosis were noted. Mean and peak transvalvular gradients significantly 
      decrease after AV replacement, with an evident reduction to approximately 50% of 
      the preoperative values at six months. A 20% reduction was also observed for left 
      ventricular mass (LVM) index at six months, with a further regression at one 
      year. Correspondingly, significant increases in effective orifice area (EOA) and 
      indexed EOA were determined after surgery (0.87 +/- 0.14 versus 1.84 +/- 0.29 cm2 
      and 0.54 +/- 0.19 versus 1.05 +/- 0.20 cm2/m2, respectively). Valve 
      prosthesis-patient mismatch was moderate in five patients and severe in one case. 
      CONCLUSIONS: Shelhigh SuperStentless AV provided good and encouraging hemodynamic 
      results. Long-term follow-up is necessary to evaluate late hemodynamic 
      performance and durability of this stentless bioprosthesis.
FAU - Cattaneo, Paolo
AU  - Cattaneo P
AD  - Department of Cardiology and Cardiac Rehabilitation Clinical Institute 
      Multimedica Holding Santa Maria, Castellanza, Varese, and Multimedica Sesto San 
      Giovanni, Milano, Italy.
FAU - Bruno, Vito Domenico
AU  - Bruno VD
FAU - Mariscalco, Giovanni
AU  - Mariscalco G
FAU - Marchetti, Paolo
AU  - Marchetti P
FAU - Ferrarese, Sandro
AU  - Ferrarese S
FAU - Salerno-Uriarte, Jorge
AU  - Salerno-Uriarte J
FAU - Sala, Andrea
AU  - Sala A
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - J Card Surg
JT  - Journal of cardiac surgery
JID - 8908809
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aortic Valve/*surgery
MH  - Aortic Valve Stenosis/*surgery
MH  - Blood Pressure
MH  - Female
MH  - Heart Rate
MH  - Heart Valve Diseases/*surgery
MH  - *Heart Valve Prosthesis
MH  - Heart Valve Prosthesis Implantation/*instrumentation
MH  - Heart Ventricles/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Postoperative Complications
MH  - Prospective Studies
MH  - *Stents
MH  - Time Factors
MH  - *Treatment Outcome
EDAT- 2007/09/07 09:00
MHDA- 2007/11/14 09:00
CRDT- 2007/09/07 09:00
PHST- 2007/09/07 09:00 [pubmed]
PHST- 2007/11/14 09:00 [medline]
PHST- 2007/09/07 09:00 [entrez]
AID - JCS430 [pii]
AID - 10.1111/j.1540-8191.2007.00430.x [doi]
PST - ppublish
SO  - J Card Surg. 2007 Sep-Oct;22(5):379-84. doi: 10.1111/j.1540-8191.2007.00430.x.